<DOC>
	<DOCNO>NCT01339481</DOCNO>
	<brief_summary>The purpose study characterize CD86 receptor occupancy subject rheumatoid arthritis ( RA ) receive abatacept .</brief_summary>
	<brief_title>A Study Assess Receptor Occupancy CD86 CD80 Subjects With Rheumatoid Arthritis Initiating Abatacept</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Subject rheumatoid arthritis ( RA ) , abatacept belataceptna√Øve , eligible candidate start course treatment abatacept accordance product label Subject willing able comply study visit procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Orencia</keyword>
	<keyword>Abatacept</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Infusion</keyword>
</DOC>